Skip to main content
SpringerLink
Log in

IMMUNE-MEDIATED KIDNEY DISEASE IN 2021

Improving outcomes in glomerular disease

  • Year in Review
  • Published:

From Nature Reviews Nephrology

View current issue Sign up to alerts

Glucocorticoid exposure remains a major contributor to morbidity and mortality in patients with immune-mediated kidney disease. Recent clinical trials have tested novel potential therapies for these patients and showed that glucocorticoid doses can be reduced without compromising efficacy.

Key advances

  • C5a receptor antagonism with avacopan is effective in combination with cyclophosphamide or rituximab for inducing and maintaining remission in severe anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and reduces glucocorticoid requirements.

  • Reducing glucocorticoid dose with rituximab for the induction of remission in AAV does not compromise short-term efficacy and reduces serious infections.

  • Use of the calcineurin inhibitor voclosporin with mycophenolate mofetil (MMF) and glucocorticoids improves renal response in patients with class III–V lupus nephritis and eGFR >45 ml/min/1.73 m2.

  • Obinutuzumab combined with MMF and glucocorticoids increases renal response in patients with class III–IV lupus nephitis.

  • Inhibition of sodium–glucose co-transporter 2 with dapagliflozin in proteinuric IgA nephropathy improves renal outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jayne, D. R. W., Merkel, P. A., Schall, T. J. & Bekker, P. Avacopan for the treatment of ANCA-associated vasculitis. N. Engl. J. Med. 384, 599–609 (2021).

    Article  CAS  Google Scholar 

  2. Walsh, M. et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N. Engl. J. Med. 382, 622–631 (2020).

    Article  CAS  Google Scholar 

  3. Furuta, S. et al. Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial. J. Am. Med. Assoc. 325, 2178–2187 (2021).

    Article  CAS  Google Scholar 

  4. Rovin, B. H. et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397, 2070–2080 (2021).

    Article  CAS  Google Scholar 

  5. Furie, R. A. et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2021-220920 (2021).

    Article  PubMed  Google Scholar 

  6. Rauen, T. et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N. Engl. J. Med. 373, 2225–2236 (2015).

    Article  CAS  Google Scholar 

  7. Lv, J. et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. J. Am. Med. Assoc. 318, 432–442 (2017).

    Article  CAS  Google Scholar 

  8. Wheeler, D. C. et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 100, 215–224 (2021).

    Article  CAS  Google Scholar 

  9. Barratt, J. & Floege, J. SGLT-2 inhibition in IgA nephropathy: the new standard of care? Kidney Int. 100, 24–26 (2021).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vasculitis and Lupus Service, Department of Renal Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

    Andreas Kronbichler & Rachel B. Jones

  2. Department of Medicine, University of Cambridge, Cambridge, UK

    Andreas Kronbichler & Rachel B. Jones

Authors
  1. Andreas Kronbichler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachel B. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rachel B. Jones.

Ethics declarations

Competing interests

A.K. has received consultancy fees from Vifor Pharma, Alexion, Otsuka and Catalyst Biosciences. R.B.J. has received grants from GSK and Roche, and has consulted for Chemocentryx, Vifor Pharma and GSK.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kronbichler, A., Jones, R.B. Improving outcomes in glomerular disease. Nat Rev Nephrol 18, 82–83 (2022). https://doi.org/10.1038/s41581-021-00526-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-021-00526-z

  • Springer Nature Limited

Search

Navigation